LEUZZI, LIVIA
LEUZZI, LIVIA
Universita' degli Studi di MILANO
A novel start‐loss mutation of the SH2B3 gene in a family with myeloproliferative neoplasms
2022 A. Beghini, L. Leuzzi, N. Abazari, L.E. Bossi, V. Guido, A. Trojani, R. Cairoli
Common Gene Expression Signature of B-Cells of Waldenstrom Macroglobulinemia (WM) and IgM Monoclonal Gammopathies of Undetermined Significance (IgM MGUS) Compared to Healthy Subjects
2021 A. Trojani, B. Di Camillo, L. Bossi, A. Greco, L. Leuzzi, A. Tedeschi, A. Frustaci, M. Deodato, G. Zamprogna, A. Melluso, A. Panzeri, M. Montillo, A. Beghini, R. Cairoli
Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenström Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma Cells
2021 A. Trojani, B. Di Camillo, L.E. Bossi, L. Leuzzi, A. Greco, A. Tedeschi, A.M. Frustaci, M. Deodato, G. Zamprogna, A. Beghini, R. Cairoli
Genetic Landscape and Clonal Evolution Patterns of CEBPA-Mutated Acute Myeloid Leukaemia Based on NextGeneration Sequencing: A Retrospective Analysis
2021 L. Leuzzi, V. Mancini, S. Veronese, L. Pezzetti, V. Motta, M. Nichelatti, R. Greco, G. Bertani, M. Montillo, A. Beghini, R. Cairoli
Update on medical treatment of small intestinal neuroendocrine tumors
2016 S. Pusceddu, D. Femia, G. Lo Russo, S. Ortolani, M. Milione, M. Maccauro, C. Vernieri, N. Prinzi, L. Concas, L. Leuzzi, F. De Braud, R. Buzzoni
Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors
2014 S. Pusceddu, F. De Braud, L. Concas, C. Bregant, L. Leuzzi, B. Formisano, R. Buzzoni